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Abstract: Excess iron causes cancer and is thought to be related to carcinogenesis and cancer
progression including stemness, but the details remain unclear. Here, we hypothesized that stemness
in cancer is related to iron metabolism and that regulating iron metabolism in cancer stem cells
(CSCs) may be a novel therapy. In this study, we used murine induced pluripotent stem cells
that expressed specific stem cell genes such as Nanog, Oct3/4, Sox2, Klf4, and c-Myc, and two
human cancer cell lines with similar stem cell gene expression. Deferasirox, an orally available iron
chelator, suppressed expression of stemness markers and spherogenesis of cells with high stemness
status in vitro. Combination therapy had a marked antitumor effect compared with deferasirox or
cisplatin alone. Iron metabolism appears important for maintenance of stemness in CSCs. An iron
chelator combined with chemotherapy may be a novel approach via suppressing stemness for CSC
targeted therapy.
Keywords: cancer stem cells; stemness; iron; combination therapy
1. Introduction
Iron is an essential element and plays crucial roles in our body, including roles in cell growth,
proliferation, DNA synthesis, and energy metabolism. On the other hand, excess iron is associated with
tumorigenesis in many types of human cancers [1–3] and is also associated with cancer progression.
These indicate that iron is an essential element for cancer cells and thought to be a therapeutic target.
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Thus, iron depletion through chelation and an iron-deficient diet have been explored as possible
therapeutic interventions in various types of cancer [4–6]. Our group has also shown the antitumor
effect of iron depletion therapy using an iron-deficient diet [7].
According to the cancer stem cell (CSC) hypothesis, CSCs exist in many types of cancer tissues
and are considered resistant to conventional types of therapy such as chemotherapy and radiation
therapy. CSCs are also related to recurrence and metastasis. CSCs have been reported in various types
of cancer [8–12]. Therapy targeting CSCs has been explored recently, but effective CSC therapy has not
been established. Iron is known to be essential for cancer and associated with tumor tumorigenesis and
cancer progression, which suggest us the existence of relationship between iron metabolism and CSCs.
Thus, we hypothesized that cancer stemness, which is strongly related to cancer malignancy, may also
be strongly related to iron metabolism and that iron depletion therapy may be a novel approach to
target CSCs.
CSCs possess the features of normal stem cells, including self-renewal and pluripotency,
in addition to cancer cell features. CSCs are distinguished by the expression of stemness markers.
From the viewpoint of stem cell hierarchy, embryonic stem cells (ES cells) possess the properties of
pluripotency and self-renewal and are at the top of the stem cell hierarchy. Several transcription
factors, including Nanog, Oct3/4, Sox2, Klf4, and c-Myc, regulate the stemness of ES cells and are
also upregulated in various types of CSCs [13–17]. Therefore, our group selected murine induced
pluripotent stem cells (miPS cells), which possess similar properties as ES cells, as a model of cells with
high stemness status and verified the effect of iron chelation using deferasirox (DFX) against stemness.
Furthermore, our group selected human cancer cell lines that express the same stemness markers as ES
cells as a model of CSCs. We verified the effect against stemness and evaluated the effectiveness of
combination therapy with DFX plus chemotherapy using cisplatin (CDDP).
2. Results
2.1. DFX Suppresses Expression of Stemness Markers and Spherogenicity of miPS Cells
To evaluate the effect of DFX on expression of stemness markers in miPS cells, the cells were
cultured with several concentrations of DFX (0, 1, 10, 50, 100 µM). DFX suppressed expression
of stemness markers at concentrations over 50 µM (Figure 1A). To evaluate the effect of DFX on
spherogenicity, a sphere formation assay was performed. DFX suppressed the spherogenicity of miPS
cells (Figure 1B). To assess the effect of DFX on cytotoxicity and morphologic changes, the Live/Dead
assay was performed. The morphology of some miPS cells changed to spindle shaped, but almost
all cells were alive after DFX treatment (Figure 1C). These results indicate that DFX suppresses the
stemness properties of miPS cells but does not induce substantial cytotoxicity.
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Figure 1. The effect of DFX against stemness of miPS cells in vitro and cytotoxicity analysis. (A) miPS 
cells were treated with the indicated dose of DFX (0, 1, 10, 50, 100 μM) and subjected to western blot 
analysis with antibodies to stemness markers (Nanog, Sox2, Oct3/4, Klf4, c-Myc) or β-actin (loading 
control). Stemness markers were suppressed by DFX at concentrations over 50 μM. (B) miPS cells 
treated with 50 μM DFX were cultured in suspension for 72 h. DFX treatment of miPS cells suppressed 
spherogenesis and GFP expression, which indicates suppression of Nanog. (C) Micrographs of the 
fluorescence-based Live/Dead assay showing live and dead miPS cells following treatment with 0.2% 
DMSO (control) or 50 μM DFX (magnification ×40). The morphology of miPS cells after treatment 
with DFX changed from round to spindle shaped. Almost all cells were stained green, which indicates 
live cells. 
2.2. DFX Suppresses Tumorigenicity and Expression of Tumor Stemness Markers in miPS Cells In Vivo 
To address the effect of DFX on tumorigenicity and expression of stemness markers in vivo, we 
employed a subcutaneous allograft model by using BALB/c nude mice. miPS cells were treated with 
0.2% dimethyl sulfoxide (DMSO) for 48 h as the control group or with 50 μM DFX for 48 h as the DFX 
group and then injected into the right flank.  
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cells were treate it t e i dicated dose of DFX (0, 1, 10, 50, 100 µM) and subjected to western blot
analysis ith antibodies to ste ness arkers (Nanog, Sox2, Oct3/4, Klf4, c-Myc) or β-actin (loading
control). Ste ness arkers were suppressed by DFX at concentrations over 50 µM. (B) miPS cells
treated with 50 µM DFX were cultured in suspension for 72 h. DFX treatment of miPS cells suppressed
spherogenesis and GFP expression, which indicates suppression of Nanog. (C) Micrographs of the
fluorescence-based Live/Dead assay showing live and dead miPS cells following treatment with 0.2%
DMSO (control) or 50 µM DFX (magnification ×40). The morphology of miPS cells after treatment
with DFX changed from round to spindle shaped. Almost all cells were stained green, which indicates
live cells.
2.2. DFX Suppresses Tu origenicity and Expression of Tumor Stemness Markers in miPS Cells In Vivo
To address the effect of DFX on tumorigenicity and expression of stemness markers in vivo,
we employed a subcutaneous allograft model by using BALB/c nude mice. miPS cells were treated
with 0.2% dimethyl sulfoxide (DMSO) for 48 h as the control group or with 50 µM DFX for 48 h as the
DFX group and then injected into the right flank.
Tumorigenesis was observed. Fourteen days after injection, tumors were harvested, and the tumor
volume and immunohistochemistry of stemness markers were evaluated. The tumorigenesis of the
DFX group was significantly suppressed compared to the control group (Figure 2A). The tumor weight
of the DFX group was also significantly suppressed compared to the control group (Figure 2B).
Immunohistochemistry and area index analysis revealed that expression of stemness markers
(Nanog, Sox2, Klf4, c-Myc) was significantly suppressed compared to the control group (Figure 2C).
Body weights of treated mice were not significantly different (Supplementary Figure S1). Thus,
DFX suppressed tumorigenesis and expression of stemness markers in tumors derived from miPS cells
in vivo.
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Figure 2. DFX suppressed tumorigenicity a d expression of stemness markers in miPS cells in vivo.
(A) miPS cells (5 × 105 per mouse) treat d wi h 0.2% DMSO or 50 µM DFX were implanted
subcutaneously i t the right flank, and tumorigenicity was evaluated. DFX significa tly suppressed
the tumor vol e of miPS cells n vivo. * p < 0.05. (B) DFX significantly suppressed the tumor weight
of miPS cells in vivo. * p < 0.05. Macroscopic images show that tumors in the DFX group were smaller
than those i t e control gr up. (C) Harvested tumors were analyzed for expression of stemness
markers (Nanog, Sox2, Oct/4, Klf4, c-Myc) by immunohistochemistry, and evaluation of the stemness
marker area index was calculated with Image J software. * p < 0.05, ** p = 0.09. Most stemness markers,
except Oct3/4, were significantly suppressed in the DFX group.
2.3. DFX Suppresses Proliferation and Expression of Stemnes Markers in Human Cancer Cell Lin
Next, to assess the effect of DFX and CDDP on cytotoxicity and expression of stemness markers
in human cancer cell lines, we used HSC-2 cells and OE33 cells, which express similar stemness
markers (Nanog, Sox2, Oct3/4, Klf4, c-Myc) as ES cells. The XTT assay showed that DFX suppressed
proliferation and expression of stemness markers (Figure 3A,B) in HSC-2 cells and OE33 cells in
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a dose-dependent manner. CDDP suppressed the proliferation of HSC-2 cells and OE33 cells in a
dose-dependent manner (Figure 3C), but expression of some stemness markers remained unchanged
or increased (Figure 3D). These results indicated that DFX effectively suppressed both proliferation
and stemness in cancer cell lines with high stemness status.Ca cers 2019, 11, x 5 of 16 
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set at 100%. (B) After culturing HSC-2 cells and OE33 cells with different concentrations of DFX for
48 h, cell lysates were collect d, and the total protein was analyzed fo expression of the indicated
stemness markers with western blot analysis. Expression of stemness markers was suppressed by DFX
in a dose-dependent manner. (C) Cultured HSC-2 cells and OE33 cells were treated with different
concentrations of CDDP for 48 h, and cell viability was evaluated with the XTT assay. CDDP suppressed
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absence of tr atm nt was set at 100%. (D) After culturing HSC-2 cells and OE33 cells with different
concentrations of CDDP for 48 h, cell lysates were collected, and the total protein was analyzed for
expression of the indicated stemness markers with western blot analysis. Most stemness markers were
upregulated or unchanged after treatment with CDDP.
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2.4. DFX Suppresses Spherogenicity in Human Cancer Cell Lines
To explore the effect of DFX on self-renewal, a sphere formation assay was performed. DFX
suppressed the spherogenicity of HSC-2 cells and OE33 cells compared to the control group (Figure 4A).
Furthermore, the average numbers of tumor spheres derived from HSC-2 cells and OE33 cells
treated with DFX were significantly decreased compared to those in the control group (Figure 4B).
To investigate the effect of Nanog, which is an upstream factor of some stemness markers [18],
on spherogenicity, HSC-2 cells were transfected with small interfering RNA against Nanog (si-Nanog),
and its interfering efficiency was measured with western blot analysis.
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OE33 cells was u ed for the spher formatio i a 96-well ultra-low ttachment plate. DFX
suppressed the spherogenicity of HSC-2 cells and OE33 cells. ( ) si gle suspension of HSC-2 cells or
OE33 cells as described above was used for the spheroid colony assay in a 24-well ultra-low attachment
plate. The number of spheres over 50 µm in diameter was counted. The experiments were performed
in triplicate, and means ± S.E.M. of each group are shown. DFX significantly suppressed the number
of spheres. * p < 0.05. (C) HSC-2 cells were transfected with control or si-Nanog for 48 h, and the
expression of stemness markers (Nanog, Sox2, Oct3/4, Klf4, c-Myc) was determined with western
blot analysis. β-actin was used as a loading control. siRNA suppressed the expression of Nanog,
Oct3/4, and Klf4. (D) HSC-2 cells were transfected with control or si-Nanog for 48 h, and the sphere
formation assay was performed. No differences were found in spherogenicity between the control and
si-Nanog cultures.
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Expression of Oct3/4 and Klf4 in addition to Nanog was suppressed by si-Nanog (Figure 4C).
However, we observed no difference in spherogenicity of HSC-2 cells after transfection with si-Nanog
(Figure 4D). Taken together, DFX suppressed not only Nanog expression but also expression of some
other stemness markers such as Sox2, Oct3/4, Klf4, and c-Myc and strongly suppressed stemness,
including spherogenicity, of HSC-2 cells and OE33 cells.
2.5. Combination Therapy with DFX and Chemotherapy Induces Synergistic Antitumor Effects in Human
Cancer Cell Lines and Suppresses Expression of Stemness Markers and Function
To evaluate the effect of combination therapy using DFX and CDDP on cytotoxicity, synergy,
and stemness in HSC-2 cells and OE33 cells, the XTT assay, combination index, and western blot
analysis were performed. The XTT assay showed that cytotoxicity of combination therapy against
HSC-2 cells and OE33 cells increased in a dose-dependent manner (Figure 5A). Combination index
analysis showed that several drug dose combinations had a synergistic effect against HSC-2 cells and
OE33 cells (Figure 5B). Western blot analysis showed that combination therapy suppressed expression
of stemness markers and induced apoptosis in HSC-2 cells and OE33 cells to a similar extent as DFX
(Figure 5C). Spherogenecity was also suppressed in combination therapy (Figure 5D). These results
indicate that combination therapy using DFX and CDDP has stronger cytotoxicity and suppression of
stemness markers and function in human cancer cell lines with high stemness status.
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in vitro. (A) Inhibition of cell growth was evaluated using the XTT assay. Combined treatment with
CDDP and DFX inhibited the growth of HSC-2 and OE33 cells in a dose-dependent manner compared
with single agent treatment. (B) The combination index was analyzed with Calcusyn software using
the results of the XTT assay. Several drug dose combinations of CDDP and DFX indicated synergism
(Combination index < 1.0) of the combination treatment. (C) Expression of stemness markers was
evaluated with western blot analysis. β-actin was used as a loading control. DFX and combination
treatment suppressed the expression of stemness markers (Nanog, Sox2, Oct3/4, Klf4, c-Myc) in HSC-2
and OE33 cells. (D) Spherogenecity was evaluated with sphere formation assay in a 96-well ultra-low
attachment plate. DFX and combination treatment suppressed the spherogenecity in HSC-2 and
OE33 cells.
2.6. Combination Therapy with DFX and Chemotherapy Suppresses Tumor Growth of Human Oral Squamous
Carcino a In Vivo
To address the effect of combination therapy on tumorigenicity and expression of stemness
markers in vivo, we employed the subcutaneous xenograft model of HSC-2 cells by using BALB/c
nude mice. DFX as administered orally concerning clinical use. Tumor volumes of control group
mice increased during the experimental period. O ly the tumor growth of the co bination group was
significantly decreased compared to the control group (Figure 6A,C). In addition, the tumor weight
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of the combination group was significantly decreased compared to the control group (Figure 6B).
Body weights of treated mice were not significantly different (Supplementary Figure S2). All mice did
not reveal significant side effects including bloody urine and rough skin. Thus, combination therapy
inhibited growth of tumors derived from HSC-2 cells in vivo.
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Figure 6. Combination therapy with DFX and CDDP is most effective in suppressing the tumor growth
of HSC-2 cells in vivo. (A) HSC-2 cells (3 × 106 per mouse) were injected subcutaneously into the right
flank of 24 mice. On day 2 when the tumors reached 150~200 mm3, mice were randomly assigned
to one of four groups (n = 6 per group), and the treatments were initiated as indicated. Tumor size
was monitored twice per week. The mean tumor volumes of each group ± S.E.M. and p values for
comparison between groups are shown. In the combination group, tumor growth of HSC-2 cells was
most effectively and significantly suppressed compared with the control group. * p < 0.05. (B) Only
the combination therapy significantly suppressed the tumor weight of HSC-2 cells in vivo. * p < 0.05.
(C) All isolated tumors are shown.
3. Discussion
In our study, we employed miPS cells as a model of ES cells, which possess high stemness status.
We also employed HSC-2 cells and OE33 cells as models of heterogeneous cancer tissue that includes
CSCs. We focused on the point that some CSCs express similar stemness transcription factors (Nanog,
Sox2, Oct3/4, Klf4, c-Myc) as ES cells. These transcription factors are important for the maintenance of
pluripotency [19–21]. DFX suppressed expression of stemness markers and spherogenesis of miPS
cells and human cancer cells and also suppressed tumorigenesis of miPS cells. To test the effect
of DFX to suppress stemness for cancer therapy, we also verified the effect of combination therapy
using DFX and chemotherapy. In vitro, we confirmed the synergistic effect of combination therapy
on cytotoxicity, suppression of expression of stemness markers, and suppression of spherogenesis.
In vivo, combination therapy showed a strong antitumor effect. Moreover, toxicity of DFX against
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human fibroblast cells (WI38, FEF3), which are non-cancerous cells, was minimal, suggesting the
potential usefulness of this combination therapy (Supplementary Figure S3).
One problem in current cancer treatment is the existence of CSCs, which are resistant to
conventional chemotherapy and radiation and are considered to be related to metastasis and
recurrence [22,23]. Some reports have shown that chemotherapy or radiation therapy induces the
generation of CSCs [24–28]. CSC targeting therapies have been extensively investigated [22,29],
but they are not yet in clinical use. Our results showed that DFX suppressed the stemness in cancer
cells with high stemness status and that combination therapy with chemotherapy may be a novel
approach against CSCs. Our group has reported that DFX suppresses stemness and tumorigenesis in a
CSC model [30]. In our current study, we have shown that this phenomenon is general and can be
applied in clinical use. We verified the effect of combination therapy with DFX and CDDP and showed
that DFX suppressed the stemness of cancer cells with high stemness status in heterogeneous cancer
tissue and that damage may be specifically directed toward these cancer cells with high stemness.
Furthermore, apoptosis was enhanced by adding CDDP to DFX. The mechanism by which DFX
suppresses stemness is unclear, but we suggest that iron metabolism may be involved in the pathway
of expression of stemness genes. According to previous reports, expression of Nanog is related to
the Stat3 signaling pathway [31–33]. Our result in which DFX suppressed the expression of Stat3
(Supplementary Figure S4) suggests that DFX may regulate the expression of Nanog.
Raggi et al. reported that iron metabolism is related to stemness of cholangiocarcinoma stem-like
cells [34]. They showed that cholangiocarcinoma stem-like cells express high levels of ferritin and
low levels of transferrin receptor 1 and ferroportin. We evaluated these iron-related markers after
DFX treatment and observed that DFX downregulated the expression of ferroportin and ferritin and
upregulated the expression of transferrin receptor (Supplementary Figure S5A,B). We also evaluated
the effect of DFX on CD44 positive cell ratio using flow cytometry. DFX decreased the CD44 positive cell
ratio (Supplementary Figure S6A). The mRNA of Nanog was suppressed by DFX in a dose-dependent
manner (Supplementary Figure S6B). These result suggests that DFX suppressed the population of
stem-like cells in HSC-2 cells and OE33 cells. Our observation that si-Nanog did not suppress the
spherogenicity of HSC-2 cells suggests that knockdown of Nanog is insufficient to suppress stemness.
On the contrary, the result in which DFX suppressed almost all stemness markers we examined
indicates that DFX may interrupt the stemness network.
As a therapeutic strategy for cancer and CSCs, attention is recently focused on iron
metabolism [35–37]. We confirmed some basic effects by iron chelator. DFX suppressed the migration
ability of CSC (Supplementary Figure S7). The ability to induce the secretion of vascular endothelial
growth factor (VEGF) in cancer cells was also revealed (Supplementary Figure S8). These results which
indicated that CSCs had a tendency to escape from an iron-depleted condition are in line with our
previous reports [7,38].
Our study has the following limitations. Although we confirmed that DFX suppressed the
expression of stemness markers in CSCs, DFX did not recognized the CSCs from cell surface antigen.
CD44 antibody includes both standard and variant isoforms. We did not check the ratio of CD44
variant isoform. We employed bulk cells as a model of heterogeneous cancer tissue and only focused
on the effect of DFX against CSCs. In addition, we did not evaluate the relapse in vivo. Further studies
are needed to evaluate the effect of DFX on other stemness markers.
We also need to confirm the status of cells after treatment with DFX. DFX may induce specific
cytotoxicity against cells with high stemness status or may lead to differentiation of such cells. Either
way, the fact that DFX suppressed stemness in cancer tissue is important and suggests that DFX may
be a useful treatment option. Thus, clarification of the mechanism is urgently needed.
In conclusion, regulating iron metabolism may be a novel strategy via suppressing stemness for
CSC targeted therapy.
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4. Materials and Methods
4.1. Cell Lines and Cell Culture
miPS cells were purchased from Riken Cell Bank (RIKEN BRC, Ibaraki, Japan). The human oral
squamous carcinoma cell line (HSC-2) was obtained from Showa University. The human esophageal
adenocarcinoma cell line (OE33) was purchased from The European Collection of Authenticated
Cell Cultures (ECACC, Salisbury, UK). We also used the human fibroblast cell lines, FEF3 and WI38,
as representative cells with a “normal” non-cancerous phenotype. FEF3 cells were isolated from human
fetal esophagus as described previously [39]. WI38 fetal lung human fibroblasts were purchased from
the Health Science Research Resource Bank (Osaka, Japan). All cells were incubated at 37 ◦C in a
humidified atmosphere containing 5% CO2.
miPS cells were maintained in medium (Dulbecco’s modified eagle medium (DMEM) containing
15% fetal calf serum (FCS), 0.1 mM non-essential amino acids, 2 mM L-glutamine, 0.1 mM
2-mercaptoethanol, 1000 U/mL leukemia inhibitory factor, 50 U/mL penicillin, and 50 U/mL
streptomycin) on feeder layers of mitomycin C-treated mouse embryonic fibroblast cells (Reprocell,
Kanagawa, Japan). HSC-2, FEF3, and WI38 cells were maintained in DMEM containing 10% FCS, 50
U/mL penicillin, and 50 U/mL streptomycin. OE33 cells were maintained in RPMI containing 10%
FCS, 50 U/mL penicillin, and 50 U/mL streptomycin.
4.2. Reagents
Deferasirox (DFX, EXJADE) was obtained from Novartis Pharma (Tokyo, Japan). For in vitro
studies, DFX was dissolved in DMSO (Sigma-Aldrich, St. Louis, MO, USA) at a stock concentration
of 50 mM. For in vivo studies, DFX was dissolved in saline. Cisplatin (CDDP, Randa) was purchased
from Nippon Kayaku (Tokyo, Japan) and dissolved in phosphate-buffered saline (PBS).
4.3. Cell Viability Assay
The XTT assay (Cell Proliferation kit II, Roche, Mannheim, Germany) was used to assess cell
proliferation according to the manufacturer’s protocol. The cells were seeded in 96-well plates and
treated with DFX and/or CDDP for 48 h at 37 ◦C. The combination index was calculated with CalcuSyn
software (BioSoft, Inc., Cambridge, UK). We seeded the cells as follows: HSC-2 (6.0 × 103/well),
OE33 (3.0 × 103/well), FEF3 and WI38 (2.0 × 103/well).
4.4. Sphere Formation Assay
Cells were seeded in 96-well ultra-low attachment plates (Corning Costar, Sigma-Aldrich) at a
density of 5 × 102 cells/well and maintained in DMEM/nutrient mixture F-12 (Sigma) containing B-27
supplement (Invitrogen, Carlsbad, CA, USA), 20 ng/mL epidermal growth factor (Sigma), 10 ng/mL
fibroblast growth factor (Sigma), 0.4% bovine serum albumin (Sigma), and 5 µg/mL insulin (Invitrogen)
for 7 days.
4.5. Live/Dead Assay
The Live/Dead viability assay was performed to assess cell viability of miPS cells after treatment
with DFX. The miPS cells were treated with 0.2% DMSO or 50 µM DFX for 48 h, rinsed with PBS,
and incubated with Calcein AM (Thermo Fisher Scientific, Waltham, MA, USA) and Ethidium
homodimer-1 (Thermo Fisher Scientific) according to the manufacturer’s protocol. Cells were
visualized using a fluorescence microscope (Olympus IX71, Olympus, Tokyo, Japan).
4.6. Nanog Small Interfering RNA Transfection
To confirm the effect of Nanog on spherogenicity, HSC-2 cells were transfected with Silencer
select siRNA against NANOG (catalog no. s36650; Ambion, Life Technologies, Carlsbad, CA, USA)
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or scrambled control (Silencer Negative Control, Ambion, Life Technologies) using Lipofectamine
RNAiMAX (Invitrogen) at a final concentration of 20 nM and 10 nM, respectively. Sphere growth was
initiated 48 h post-transfection.
4.7. Western Blotting
Protein was extracted from whole cells after 48 h of incubation in medium and reagents.
The concentrations of extracted protein were measured using standard protocols. Cells were lysed
using cell lysis buffer (50 mmol/L Tris-HCl (pH 7.4), 30 mmol/L NaCl, and 1% Triton X-100) containing
protease inhibitors (cOmplete Mini, Roche Diagnostics GmbH, Basel, Switzerland). Equal amounts
of total cellular proteins (50 µg/lane) were separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and transferred electrophoretically to polyvinylidene difluoride filter membranes (GE
Healthcare UK Ltd., Buckinghamshire, UK) according to the manufacturer’s protocol. The following
primary antibodies were used: anti-Nanog antibody (catalog no. 4903S; Cell Signaling Technology,
Danvers, MA, USA), anti-Sox2 antibody (catalog no. ab97959; Abcam, Cambridge, MA, USA),
anti-Oct3/4 antibody (catalog no. MAB1759; R&D Systems, Minneapolis, MN, USA), anti-KLF4
antibody (catalog no. ab72543; Abcam), anti-c-Myc antibody (catalog no. ab32072; Abcam),
anti-transferrin receptor antibody (catalog no. ab84036; Abcam), anti-DMT1 antibody (catalog
no. ab123085; Abcam), anti-ferroportin/SLC40A1 antibody (catalog no. NBP1-21502; Novus
Biologicals, Littleton, CO, USA), anti-ferritin heavy chain antibody (catalog no. ab65080; Abcam),
anti-β-actin antibody (catalog no. A5441; Sigma-Aldrich), anti-PARP antibody (catalog no. 9542; Cell
Signaling Technology), anti-cleaved caspase-3 antibody (catalog no. 9664; Cell Signaling Technology),
anti-caspase 3 antibody (catalog no. sc-7148; Santa Cruz, Dallas, TX, USA), anti-Stat3 antibody
(catalog no. 12640; Cell Signaling Technology), and anti-phospho-Stat3 antibody (catalog no. 9145;
Cell Signaling Technology). All primary antibodies were used at a 1:1000 dilution. The following
secondary antibodies were used: anti-Mouse IgG, HRP-Linked Whole antibody Sheep (catalog no.
NA931; GE Healthcare, UK Ltd.), anti-Rabbit IgG, HRP-Linked Whole antibody Donkey (catalog
no. NA934; GE Healthcare, UK Ltd.), anti-Rat IgG, HRP-Linked Whole antibody Goat (catalog no.
NA935; GE Healthcare, UK Ltd.). All secondary antibodies (GE Life Sciences) were used at a 1:2500
dilution. The membranes were incubated with primary antibodies overnight at 4 ◦C, followed by
incubation with secondary antibodies. ECL prime Western Blotting Detection Reagent (GE Healthcare
UK Ltd.) was used to detect the peroxidase activity of secondary antibodies. Membranes were probed
for β-actin as a loading control, and all sample data values were normalized to the corresponding
control data values. Densitometric analysis was performed using Image J software (NIH).
4.8. Flow Cytometry Analysis
HSC-2 and OE-33 cells were seeded at 5× 104 cells/mL in 6 well plates 24 h before treatment with
different concentrations of DFX for 48h, after which cells and medium were recovered, centrifuged
(5 min, 400 g, 4 ◦C). Cells were suspended in PBS containing 2% fetal bovine serum and 0.1%
sodium azide, and stained with the anti-mouse/human CD44 Antibody (Cat. No.103015, BioLegend,
San Diego, CA, USA) and propidium iodide staining (Life Technologies Corporation) after 10 min of
pre-incubation with human TruStain FcX (Fc Receptor Blocking Solusion, BioLegend Cat. No. 422301).
Cell fluorescence was detected with MACSQuant Analyzer (Miltenyi Biotec, Bergisch Gladbach,
Germany) and analyzed with MACSQuantify Software.
4.9. Real-Time Quantitative PCR
HSC-2 and OE-33 cells were seeded at 5 × 104 cells/mL in 6 well plates 24 h before treatment
with different concentrations of DFX for 48 h. Total RNA was isolated from HSC-2 and OE-33 cells
using Trizol Reagent (Gibco BRL, Grand Island, NY, USA) and High Pure RNA Isolation kit (Roche
Applied Science, Basel, Switzerland), respectively. First-strand cDNA was constructed from total RNA
using the oligo (dT) primer. Real-time quantitative PCR analysis was performed using StepOne with
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Taqman PCR master mix (Applied Biosystems, Foster City, CA, USA). The primers used in this study
were: GAPDH (Applied Biosystems) and Nanog (Integrated DNA Technologies, Coralville, USA).
The quantification of the gene of interest was normalized to GAPDH and expressed as fold-increases
relative to the negative control for each treatment at each time point as previously described.
4.10. VEGF ELISA Assay
To evaluate the supernatant VEGF secreted by HSC-2 and OE33 cells, we used a VEGF
enzyme-linked immunosorbent assay (ELISA) kit (Proteintech, Rosemont, IL, USA). The cancer
cells were plated in 6 well plates and were treated with different concentrations of DFX. After a
48-h treatment, the supernatant and cells were harvested and VEGF content was assayed by ELISA
according to the protocol provided by the manufacturer.
4.11. Tumor Xenograft Model and Experiment
All animal experiments were performed according to the Japanese Welfare and Management of
Animals Act and conducted in accordance with institutional guidelines at Shigei Medical Research
Institute, Okayama, Japan. All animal experiments were approved by the Ethics Review Committee
for Animal Experimentation of Shigei Medical Research Institute (#160401-1), Okayama, Japan. Female
BALB/c (nu/nu) mice were purchased from CLEA Japan (Tokyo, Japan). Female BALB/c (nu/nu)
mice were purchased from CLEA Japan. The experiment started when the mice were 9 weeks of
age. HSC-2 cells in culture were harvested and resuspended in a 1:1 ratio of PBS and Matrigel (BD
Biosciences). HSC-2 cells (3.0 × 106) were injected subcutaneously into the right flank. When the
tumor size reached 150~200 mm3, the mice were randomly divided into four groups (control group,
CDDP group, DFX group, combination group, n = 6 per group). Each group was treated with oral
gavage of saline or DFX (160 mg/kg) three times per week for 3 weeks and by intraperitoneal injection
of saline or CDDP (6 mg/kg) once per week for 3 weeks. Tumor size and body weight were measured
every 3 days. The tumor volume (mm3) was calculated with the formula d2 × D/2 where d and D are
the shortest and longest diameters in mm, respectively. At the end of the experiment, the mice were
sacrificed, and the tumors were excised, weighed, and processed for histological analysis.
4.12. Immunohistochemistry of In Vivo-Derived Tumor Tissues
Harvested tumors were fixed in 10% paraformaldehyde and embedded in paraffin prior to
immunostaining. The same anti-Nanog antibody, anti-Sox2 antibody, anti-Oct3/4 antibody, anti-KLF4
antibody, and anti-c-Myc antibody were used as described in the western blot analysis section.
Evaluation of the Nanog, Sox2, Oct3/4, KLF4, and c-Myc area index was performed with Image
J software (http://rsb.info.nih.gov/ij/).
4.13. Statistical Analysis
All statistical analyses were performed with SPSS advanced statistics 16.0 software (SPSS, Tokyo,
Japan). For two-group comparisons, Student’s t-test was used. For multiple-group comparisons,
analysis of variance with Tukey’s test was used. p values < 0.05 were considered statistically significant.
5. Conclusions
In conclusion, to the best of our knowledge, iron metabolism appears important for maintenance
of stemness in cell lines with high stemness status including CSCs. The expression of stemness
markers such as Nanog, Oct3/4, Sox2, Klf4, and c-Myc was suppressed by iron chelator. By using iron
chelator, regulating iron metabolism and combined with chemotherapy may be a novel strategy for
CSC targeted therapy via suppressing stemness.
Cancers 2019, 11, 177 14 of 16
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/2/177/s1,
Figure S1: miPS cells (5 × 105 per mouse) treated with 0.2% DMSO or 50 µM DFX were implanted subcutaneously
into the right flank, and tumorigenicity was evaluated. There were no significant differences between groups.
Data are represented as average ± S.E.M. (n = 5), Figure S2: HSC-2 cells (3 × 106 per mouse) were injected
subcutaneously into the right flank of 24 mice. On day 2 when the tumors reached 150~200 mm3, mice were
randomly assigned to one of four groups (n = 6 per group), and the treatments were initiated as indicated.
The mean body weight of each group ± S.E.M. for comparison between groups are shown. There were no
significant differences between groups, Figure S3: Cultured WI38 cells and FEF3 cells were treated with different
concentrations of DFX for 48 h, and cell viability was evaluated with the XTT assay. The cytotoxity of DFX against
WI38 cells and FEF3 was very low. Cell viability in the absence of treatment was set at 100%, Figure S4: Experiment
of Nanog, Stat3 and phosho-Stat3 was evaluated with western blot analysis. β-actin was used as a loading control.
DFX and combination treatment suppressed the expression of Nanog, Stat3 and phosho-Stat3 in HSC-2 cells,
Figure S5: (A) Experiment of iron-related markers (FPN, FtH, TfR, DMT-1) was evaluated with western blot
analysis. β-actin was used as a loading control. DFX suppressed the expression of iron-related markers except
TfR in HSC-2 and OE33 cells. (B) Densitometric analysis of western blot also showed that DFX suppressed the
expression of iron-related markers except TfR in HSC-2 and OE33 cells. Statistical significance was determined as *
p ≤ 0.05, Figure S6: (A) HSC-2 and OE33 cells treated with different concentrations of DFX for 48 h were analyzed
by flow cytometry. CD44 antibody was used as a stemness marker. Living CD44 positive cells ratio was decreased
by DFX. (B) Total RNA of HSC-2 and OE33 cells treated with DFX with indicated concentrations were used in the
PCR analysis. The mRNA of Nanog was suppressed by DFX in a dose-dependent manner. Relative expression
level in the absence of treatment was set at 1. Statistical significance was determined as * p ≤ 0.05, Figure S7: (A)
Experiment of migration ability was performed with scratch assay. HSC-2 and OE33 cells were seeded in 6well
plates and treated with different concentrations of DFX. Migration ability was evaluated with indicated time. DFX
suppressed the migration ability in HSC-2 and OE33 cells. (B) Scratch assay was quantitively analyzed as area of
gap with Image J software. * p < 0.05. Scratched area was remained by DFX in a dose-dependent manner, Figure
S8: Experiment of vascular endothelial growth factor secretion was performed with ELISA assay. The supernatant
was collected with indicated concentration of DFX. DFX induced vascular endothelial growth factor secretion in
HSC-2 and OE33 cells.
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